Chronic Myeloid Leukemia
Chronic Myeloid Leukemia (CML)
Chronic Myeloid Leukemia (CML) is a slow-growing cancer of the bone marrow that results in the overproduction of white blood cells. It is unique because nearly all cases (approx. 95%) are caused by a specific genetic abnormality known as the Philadelphia chromosome.
When You Should Consider CML Evaluation
Persistent fatigue or weakness.
Drenching night sweats.
Fullness or discomfort on the left side of the abdomen due to an enlarged spleen.
Unexplained weight loss or mild fevers.
Many patients have no symptoms and are diagnosed during routine blood tests.
Methods of CML Classification
Chronic Phase: The most common stage at diagnosis (85–90% of patients) where symptoms are mild and the disease responds well to standard treatment.
Accelerated Phase: The cancer grows faster with blast counts rising to 10–19%, and symptoms become more noticeable.
Blast Phase (Blast Crisis): An aggressive stage with 20% or more blasts that behaves like acute leukemia and is harder to treat.
Genetic Cause: Driven by the BCR-ABL gene, created when pieces of chromosomes 9 and 22 swap places.
How CML Treatment Is Performed
TKI Therapy: Daily oral pills such as Imatinib (Gleevec), Dasatinib (Sprycel), or Nilotinib (Tasigna) that specifically "turn off" the BCR-ABL protein.
Hematologic Management: Normalizing blood counts, which typically occurs within the first few weeks of treatment.
Molecular Monitoring: Using sensitive PCR tests to measure and reduce the level of the BCR-ABL gene in the blood.
Treatment-Free Remission (TFR): For eligible patients who maintain a deep response, stopping medication under strict medical supervision.
Pre-Procedure Preparation
Understanding that CML is now a manageable chronic condition requiring consistent, long-term medication.
Establishing a baseline through physical exams and medical history to check for an enlarged spleen.
Discussing the importance of adherence to daily oral therapy to achieve a Major Molecular Response.
Planning for frequent initial monitoring to ensure the "genetic switch" is being effectively turned off.
Tests Before CML Treatment
Bone Marrow Biopsy: To confirm the diagnosis and determine the phase of the disease.
FISH or PCR Testing: Highly sensitive blood tests used to detect the Philadelphia chromosome and the BCR-ABL gene.
Complete Blood Count (CBC): To evaluate the levels of abnormal white blood cells.
Cytogenetic Analysis: To identify the physical exchange of genetic material between chromosomes 9 and 22.
Life After CML Treatment
Life expectancy for those in the chronic phase is now approaching that of the general population.
The 5-year survival rate is currently over 90%, compared to roughly 20% before the year 2000.
Patients require lifelong monitoring to ensure the disease remains in molecular remission.
Most patients can maintain a normal lifestyle while taking daily oral targeted therapy.
Benefits of CML Treatment
Revolutionizes the prognosis from a once-fatal disease to a manageable chronic condition.
Specifically targets the genetic "stuck switch" (BCR-ABL) without the need for traditional intensive chemotherapy.
Achieves Major Molecular Response, making the cancer gene nearly undetectable in the blood.
Offers the potential for treatment-free remission in patients with deep, sustained responses.
